Clinical trials
Lung Cancer Stage II clinical trials
Below are recruiting lung cancer stage ii clinical trials, each written for real people, not researchers. We’re tracking 329 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06931717RecruitingPhase 3
Immunotherapy after lung cancer surgery for those not getting chemo
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
ViennaAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Fresno, CaliforniaAges 18 years+ - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Tampa, FloridaAges 18 years+ - NCT06080776RecruitingPhase 3
SH-1028 vs placebo for early-stage EGFR-mutated lung cancer
This trial tests a pill called SH-1028 (an EGFR-targeted drug) versus a placebo to see if it helps prevent lung cancer from coming back after surgery in people with EGFR-mutated NSCLC. You may be eligible if you had complete removal of stage II-IIIB NSCLC and your tumor has a specific EGFR mutation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06868836RecruitingPhase 2
Study of a new antibody combination for advanced lung cancer after targeted therapy
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT07089199RecruitingPhase 2
Treatment before surgery for stage 2–3 lung cancer
This study tests whether giving a combination of three medicines before surgery can help shrink tumors in people with stage 2 or 3 non-small cell lung cancer, potentially making surgery and recovery more effective. The medicines include an immunotherapy drug (tislelizumab), a targeted therapy (anlotinib), and a chemotherapy drug (nab-paclitaxel).
Jinan, ShandongAges 18–75 - NCT06312137RecruitingPhase 3
Pembrolizumab with or without another drug for lung cancer after surgery
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Little Rock, ArkansasAges 18 years+ - NCT06121505RecruitingPhase 2
Low-dose radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding low-dose radiation and a type of targeted radiation (SBRT) to a combination of immunotherapy (sintilimab) and chemotherapy works better than immunotherapy and chemotherapy alone for people with advanced squamous cell lung cancer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07743021Recruiting
Blood sample study for better health screening
This study collects blood samples and health information over time to improve early detection of diseases. It may help researchers find ways to prevent serious conditions.
BalatonfüredAges 40 years+ - NCT04973293Recruiting
Pre-surgery immunotherapy plus chemo and blood-vessel medicine for lung cancer
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06613165Recruiting
Short vs long treatment for stage II-III rectal cancer with dMMR
This trial tests how long you need a PD-1 immunotherapy before surgery for a specific type of rectal cancer (dMMR/MSI-H). It looks at whether a shorter or longer course works best. This could mean fewer side effects and a quicker path to surgery.
Xi'an, ShaanxiAges 18–80 - NCT04286841Recruiting
Immunotherapy before lung surgery for early lung cancer
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
Guangzhou, GuangdongAges 18 years+ - NCT06426511RecruitingPhase 2
Testing toripalimab after lung cancer surgery using ctDNA
This study tests whether a drug called toripalimab, given after lung cancer surgery, can help keep the cancer from coming back in people with early-stage non-small cell lung cancer. It uses a blood test (ctDNA) to look for leftover cancer cells and decide who might benefit most.
Guangzhou, GuangdongAges 18–75 - NCT01803542RecruitingPhase 2
Stereotactic radiation for lung metastases or early lung tumors
This trial studies a precise, high-dose radiation technique (SBRT) to treat tumors in the lungs. It may help control cancer in people who either have early-stage lung cancer that is not fully operable or have limited lung metastases from other cancers.
Toronto, OntarioAges 18 years+ - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
Tampa, FloridaAges 18 years+ - NCT05723250Recruiting
Rural early cancer care coaching and education program
This study tests an educational “care coordination” program to help people living in rural Vermont manage care during the early stages of breast, lung, or colon cancer treatment. It may help you feel more supported and organized while starting or preparing for chemotherapy.
Burlington, VermontAges 18 years+ - NCT05239546RecruitingPhase 2
Dostarlimab before colon surgery for mismatch-repair–deficient cancer
This study tests dostarlimab given before surgery for stage II or III colon cancer that has a specific DNA repair defect. It aims to shrink or control the cancer so that some people may be able to skip surgery if the results are good.
Iowa City, IowaAges 18 years+ - NCT06873555RecruitingPhase 1/Phase 2
Study of a new drug for ovarian cancer and other advanced solid tumors
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
Bengbu, AnhuiAges 18 years+ - NCT07855965RecruitingPhase 2
Ablation with immunotherapy and chemo before lung cancer surgery
This study tests a new approach for people with early-stage lung cancer that can be removed with surgery. Before surgery, patients receive a treatment called cryo-thermal ablation to freeze and heat the tumor, along with an immunotherapy drug (toripalimab) and chemotherapy. The goal is to see if this combination shrinks tumors and improves outcomes after surgery.
Chengdu, SichuanAges 18–80 - NCT07085182RecruitingPhase 2
Tislelizumab plus radiation for advanced lung cancer
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Zibo, ShandongAges 18–75 - NCT07284992RecruitingPhase 2
Comparing short vs long radiation with immunotherapy for rectal cancer
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
Jinan, ShandongAges 18–80 - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07082179RecruitingPhase 2
Immunotherapy plus chemotherapy for stage III lung cancer
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
NanjingAges 18–75
Hear when a new Lung Cancer Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer stage ii?
- Yes. Clin2 currently lists 329 recruiting lung cancer stage ii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer stage ii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer stage ii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.